Dorien Baetens1, Tülay Güran2, Berenice B Mendonca3, Nathalia L Gomes3, Lode De Cauwer4,5, Frank Peelman4,5, Hannah Verdin1, Marnik Vuylsteke6, Malaïka Van der Linden7, Zeynep Atay, Abdullah Bereket, Ronald R de Krijger, Katleen de Preter, Sorahia Domenice, Serap Turan, Hans Stoop8, Leendert H Looijenga8, Karolien De Bosscher4,5, Martine Cools9, Elfride De Baere10. 1. Center for Medical Genetics, Ghent University and Ghent University Hospital, Ghent, Belgium. 2. Zeynep Kamil Maternity and Children's Diseases Training and Research Hospital, Division of Pediatric Endocrinology and Diabetes, Istanbul, Turkey. 3. Disciplina de Endocrinologia, Laboratorio de Hormonios e Genetica Molecular LIM/42, Unidade de Adrenal, Disc. de Endocrinologia e Metabologia, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil. 4. Receptor Research Laboratories, Nuclear Receptor Lab, Department of Medical Protein Research, VIB, Ghent, Belgium. 5. Department of Biochemistry, Ghent University, Ghent, Belgium. 6. GNOMIXX ltd, Statistics for Genomics, Melle, Belgium. 7. Department of Medical and Forensic Pathology, Ghent University and Ghent University Hospital, Ghent, Belgium. 8. Department of Pathology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. 9. Department of Pediatrics, Division of Pediatric Endocrinology, Ghent University and Ghent University Hospital, Ghent, Belgium. 10. Center for Medical Genetics, Ghent University and Ghent University Hospital, Ghent, Belgium. Elfride.DeBaere@ugent.be.
Abstract
PURPOSE: Disorders or differences of sex development (DSDs) are rare congenital conditions characterized by atypical sex development. Despite advances in genomic technologies, the molecular cause remains unknown in 50% of cases. METHODS: Homozygosity mapping and whole-exome sequencing revealed an ESR2 variant in an individual with syndromic 46,XY DSD. Additional cases with 46,XY DSD underwent whole-exome sequencing and targeted next-generation sequencing of ESR2. Functional characterization of the identified variants included luciferase assays and protein structure analysis. Gonadal ESR2 expression was assessed in human embryonic data sets and immunostaining of estrogen receptor-β (ER-β) was performed in an 8-week-old human male embryo. RESULTS: We identified a homozygous ESR2 variant, c.541_543del p.(Asn181del), located in the highly conserved DNA-binding domain of ER-β, in an individual with syndromic 46,XY DSD. Two additional heterozygous missense variants, c.251G>T p.(Gly84Val) and c.1277T>G p.(Leu426Arg), located in the N-terminus and the ligand-binding domain of ER-β, were found in unrelated, nonsyndromic 46,XY DSD cases. Significantly increased transcriptional activation and an impact on protein conformation were shown for the p.(Asn181del) and p.(Leu426Arg) variants. Testicular ESR2 expression was previously documented and ER-β immunostaining was positive in the developing intestine and eyes. CONCLUSION: Our study supports a role for ESR2 as a novel candidate gene for 46,XY DSD.
PURPOSE: Disorders or differences of sex development (DSDs) are rare congenital conditions characterized by atypical sex development. Despite advances in genomic technologies, the molecular cause remains unknown in 50% of cases. METHODS: Homozygosity mapping and whole-exome sequencing revealed an ESR2 variant in an individual with syndromic 46,XY DSD. Additional cases with 46,XY DSD underwent whole-exome sequencing and targeted next-generation sequencing of ESR2. Functional characterization of the identified variants included luciferase assays and protein structure analysis. Gonadal ESR2 expression was assessed in human embryonic data sets and immunostaining of estrogen receptor-β (ER-β) was performed in an 8-week-old human male embryo. RESULTS: We identified a homozygous ESR2 variant, c.541_543del p.(Asn181del), located in the highly conserved DNA-binding domain of ER-β, in an individual with syndromic 46,XY DSD. Two additional heterozygous missense variants, c.251G>T p.(Gly84Val) and c.1277T>G p.(Leu426Arg), located in the N-terminus and the ligand-binding domain of ER-β, were found in unrelated, nonsyndromic 46,XY DSD cases. Significantly increased transcriptional activation and an impact on protein conformation were shown for the p.(Asn181del) and p.(Leu426Arg) variants. Testicular ESR2 expression was previously documented and ER-β immunostaining was positive in the developing intestine and eyes. CONCLUSION: Our study supports a role for ESR2 as a novel candidate gene for 46,XY DSD.
Authors: Soumia Brakta; Lynn P Chorich; Hyung-Goo Kim; Laurel A Coons; John A Katzenellenbogen; Janet E Hall; Kenneth S Korach; Lawrence C Layman Journal: J Clin Endocrinol Metab Date: 2020-05-01 Impact factor: 5.958
Authors: Fuad Chowdhury; Lei Wang; Mohammed Al-Raqad; David J Amor; Alice Baxová; Šárka Bendová; Elisa Biamino; Alfredo Brusco; Oana Caluseriu; Nancy J Cox; Tawfiq Froukh; Meral Gunay-Aygun; Miroslava Hančárová; Devon Haynes; Solveig Heide; George Hoganson; Tadashi Kaname; Boris Keren; Kenjiro Kosaki; Kazuo Kubota; Jennifer M Lemons; Maria A Magriña; Paul R Mark; Marie T McDonald; Sarah Montgomery; Gina M Morley; Hidenori Ohnishi; Nobuhiko Okamoto; David Rodriguez-Buritica; Patrick Rump; Zdeněk Sedláček; Krista Schatz; Haley Streff; Tomoko Uehara; Jagdeep S Walia; Patricia G Wheeler; Antje Wiesener; Christiane Zweier; Koichi Kawakami; Ingrid M Wentzensen; Seema R Lalani; Victoria M Siu; Weimin Bi; Tugce B Balci Journal: Genet Med Date: 2021-04-06 Impact factor: 8.822
Authors: L Audi; S F Ahmed; N Krone; M Cools; K McElreavey; P M Holterhus; A Greenfield; A Bashamboo; O Hiort; S A Wudy; R McGowan Journal: Eur J Endocrinol Date: 2018-10-01 Impact factor: 6.664
Authors: Clara Valeri; María M Lovaisa; Chrystèle Racine; Nadia Y Edelsztein; Marina Riggio; Sebastián Giulianelli; Marcela Venara; Patricia Bedecarrás; María G Ballerini; Nathalie di Clemente; Caroline A Lamb; Helena F Schteingart; Rodolfo A Rey Journal: Sci Rep Date: 2020-09-15 Impact factor: 4.379